# Tamoxifen to Prevent Bone Loss and Heart Disease in Premenopausal Women Receiving Chemotherapy for Stage I or Stage II Breast Cancer

> **NCT00005605** · — · COMPLETED · sponsor: **Northwestern University** · enrollment: 79 (actual)

## Conditions studied

- Breast Cancer
- Osteoporosis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT00005605
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2000-02
- **Primary completion:** 2005-10
- **Final completion:** 2005-10
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2011-02-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00005605

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00005605, "Tamoxifen to Prevent Bone Loss and Heart Disease in Premenopausal Women Receiving Chemotherapy for Stage I or Stage II Breast Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00005605. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*